MedTrace Logo

Evaluation Study of New Compounds With Potential Use in Schizophrenia

NCT00916201 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2025-03-21

No results posted yet for this study

Summary

Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.

Conditions

Interventions

DRUG

URB597

10 mg / d for 5 days, orally

DRUG

intranasal Insulin

160 IU / d for 5 days, intranasal

DRUG

Cannabidiol CR

320 mg / d for 5 days, orally

Sponsors & Collaborators

  • Max Planck Institute for Metabolism Research

    collaborator OTHER

  • Central Institute of Mental Health, Mannheim

    lead OTHER

Principal Investigators

  • F. Markus Leweke, MD · Central Institute of Mental Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916201 on ClinicalTrials.gov